Synchron Raises $200 Million to Advance Brain-Computer Interface for Paralysis
Synchron has secured $200 million in a Series D funding round to expand its operations and speed up the commercialization of its non-surgical brain-computer interface (BCI) designed to help people with paralysis.
Funding Details and Investors
The round was led by Double Point Ventures and included participation from existing investors such as Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI, and Metis. Additional investors were the Australian National Reconstruction Fund, T.Rx Capital, the Qatar Investment Authority, K5 Global, Protocol Labs, and IQT.
Company Progress and Industry Context
This funding brings Synchron’s total capital raised to $345 million and comes during a period of increasing momentum within the BCI industry. The company is focused on non-surgical solutions to improve quality of life for individuals with paralysis.
Recent Developments in BCI
- Precision Neuroscience recently announced a partnership with SCI Ventures, supported by the Christopher & Dana Reeve Foundation, to develop its Layer 7 Cortical Interface.
- Science Corp. reported that its PRIMA BCI retinal implant restored some vision to patients with severe age-related macular degeneration.
"Synchron has reeled in another $200 million in a series D round—cash the company said it will use to expand operations and accelerate commercialization of its nonsurgical brain-computer interface for people with paralysis."
Author's summary: Synchron's significant new funding underscores growing interest and progress in non-invasive brain-computer interfaces to enhance life quality for people with paralysis.